Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. (ARTV) priced its initial public offering on Jul 22, 2024 at $12.00 per share, below its $14.00–$16.00 range, raising $167M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $279.4M. Jefferies was lead-left underwriter, joined by TD Cowen, Cantor and Wedbush and others. Cooley advised the company and Latham & Watkins advised the underwriters.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing natural killer (NK) cell therapies for autoimmune diseases and cancers. Its lead candidate, AlloNK, is a donor-derived, cryopreserved NK cell therapy being studied with B-cell targeted antibodies in a Phase 1/1b trial in systemic lupus erythematosus.

Status

IPO

Ticker

ARTV

Exchange

Nasdaq Global Market

Priced

Jul 22, 2024

IPO price

$12.00

Price range

$14.00–$16.00

Raised

$167M

Market cap at IPO price

$279.4M

First filed

Apr 8, 2021

Underwriters

Jefferies, TD Cowen, Cantor, Wedbush and Needham

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.